By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventors McCulloch, James Stanley; Kelly, Steven Dale, filed on April 23, 2015, was made available online on August 20, 2015, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not
Release date- 02092015- AstraZeneca today announced positive topline results from RECAPTURE 1 and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic, CAZ-AVI, as a treatment for adult hospitalised patients with complicated Urinary Tract Infections, including pyelonephritis. In the US, where AstraZeneca's partner Allergan holds the
BioTime reported that subsidiary Asterias Biotherapeutics, a biotechnology company focused on the emerging field of regenerative medicine, reported that the third patient was successfully dosed at Chicago- based Rush University Medical Center in a Phase 1/ 2 a clinical trial evaluating activity of escalating doses of AST-OPC1 in newly injured patie
The All Wales Medicines Strategy Group has approved the use of pomalidomide in relapsed and refractory myeloma- a cancer which affects 230 people in Wales each year. Wales is only the second country in the UK to routinely approve Imnovid for myeloma patients, following on from the Scottish Medicines Consortium in December. Kate Morgan, the policy a
-BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced the presentation of an investigator initiated study supporting its lead compound, Plinabulin, at the upcoming 16th World Conference on Lung Cancer, which is hosted by the International Associatio
Eleven Biotherapeutics reported the promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to Senior Vice President, Finance. "Gary and John have demonstrated strong leadership and played critical roles in advancing Eleven to this point in the company's growth," said Abbie Celniker, PhD, President and Chief Executiv
-Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of DMF for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company's Chief Financial Officer, will participate in the following conferences:. Wells Fargo 2015 Healthcare Conference to be held at the Hyatt R
Dublin- Research and Markets has announced the addition of the "Global Royalty Financing Deals in Pharma, Biotech and Diagnostics 2010-2015" report to their offering. The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 report is your one-stop source for providing real-deal information on hundreds of transactions, including the
GlycoMimetics reported that the U.S. Patent and Trademark Office has issued a composition of matter patent, entitled "E-Selectin Antagonist Compounds, Compositions and Methods of Use," which provides coverage for the chemical structure of GlycoMimetics' clinical product candidate GMI-1271. "This patent issuance represents an important step for...
Dublin- Research and Markets has announced the addition of the "Huntington's Disease- Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of a
KMART Corp., a discount department store chain that operates approximately 780 in-store pharmacies throughout the United States, Puerto Rico and the U.S. Virgin Islands, has paid the United States $1.4 million to resolve allegations that it violated the False Claims Act by using drug manufacturer coupons and gasoline discounts as improper Medicare.
MediciNova, Inc. today announced that the first advanced ALS patient, using non-invasive ventilation, has enrolled in the Phase 2 clinical trial evaluating MN-166 in both early and advanced stage ALS. MediciNova amended the protocol to expand its recruitment to include advanced ALS patients in the trial, and this amendment was approved by FDA.
ALEXANDRIA, Va., Sept. 3 Molecular Insight Pharmaceuticals, Tarrytown, New York, has been assigned a patent developed by seven co-inventors for "metal complexes of poly amine-containing ligands having an affinity for carbonic anhydrase IX." The co-inventors are John W. Babich, New York, Craig Zimmerman, Topsfield, Massachusetts, John L. Joyal, Me
The All Wales Medicines Strategy Group has approved the use of pomalidomide in relapsed and refractory myeloma- a cancer which affects 230 in Wales each year. Wales is only the second country in the UK to routinely approve Imnovid for myeloma patients, following on from the Scottish Medicines Consortium in December. Kate Morgan, the policy and publ
-Ocera Therapeutics, Inc., a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases today announced that Linda Grais, M.D., chief executive officer, will be presenting at the Rodman& Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York City, NY. Ocera Therapeutics, Inc.
Dublin- Research and Markets has announced the addition of the "Refractory Acute Myeloid Leukemia- Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by d
ALEXANDRIA, Va., Sept. 3 Regeneron Pharmaceuticals, Tarrytown, New York, has been assigned a patent developed by four co-inventors for "human antibodies to human angiopoietin-like protein 4." The co-inventors are Mark W. Sleeman, Mahopac, New York, Viktoria Gusarova, Springfield, New Jersey, Jee H. Kim, White Plains, New York, and Gang Chen, York
Researchers Submit Patent Application, "Use of Non-Peptidic Nk1 Receptor Antagonists for the Production of Apoptosis in Tumor Cells", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventor MUNOZ S EZ, Miguel, filed on April 23, 2015, wa
Novartis International AG/ Sandoz launches ZarxioTM, the first biosimilar in the United States. *Launch follows March 6, 2015 FDA approval* Sandoz One Source (TM) offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen, September 3, 2015- Sandoz, a Novartis company, announced today that Za
Novartis today announced that the European Commission has approved the combination of Tafinlar and Mekinist for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Marketing authorization is based on results from the Phase III COMBI-d and COMBI- v studies, in which the Tafinlar/Mekinist combination...
Myeloma Canada reported the first major contribution by a pharmaceutical or biotechnology company supporting the formalization of the Myeloma Canada Research Network. According to a release from the company, Karyopharm Therapeutics has made a significant donation to further the development of the MCRN in helping achieve its goal of advancing...
Bristol-Myers Squibb Company and AbbVie reported the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for Empliciti, an investigational Signaling Lymphocyte Activation Molecule- directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in patients who have..
Xerox and inVentiv Health today announced Xerox s acquisition of inVentiv Patient Access Solutions, an inVentiv Health company. The acquisition will expand Xerox s pharmacy solutions portfolio with an offering to help pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement...
Xerox and inVentiv Health reported Xerox's acquisition of inVentiv Patient Access Solutions, an inVentiv Health company. Xerox said the acquisition will expand its pharmacy solutions portfolio with an offering to help pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement...
Zeiss Medical Technology reported that its AngioPlex OCT Angiography is the first such technology to receive 510 clearance from the U.S. Food and Drug Administration. With a single additional OCT scan that takes just seconds on the CIRRUS HD-OCT system from Zeiss, the company said, ophthalmologists can now utilize optical coherence tomography image